Shopping Cart
- Remove All
Your shopping cart is currently empty
Pan-RAS-IN-1
🥰Excellent
Catalog No. T16432Cas No. 1835283-94-7
Pan-RAS-IN-1 is an inhibitor of pan-Ras. It disrupts the interaction of Ras proteins and their effectors.
Pan-RAS-IN-1
🥰Excellent
Purity: 98.57%
Catalog No. T16432Cas No. 1835283-94-7
Pan-RAS-IN-1 is an inhibitor of pan-Ras. It disrupts the interaction of Ras proteins and their effectors.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $73 | In Stock | |
| 2 mg | $98 | In Stock | |
| 5 mg | $147 | In Stock | |
| 10 mg | $228 | In Stock | |
| 25 mg | $463 | In Stock | |
| 50 mg | $695 | In Stock | |
| 100 mg | $987 | In Stock | |
| 500 mg | $1,980 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $233 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Pan-RAS-IN-1"
sodium lauroyl-α-hydroxyethyl sulfonate
T7283112714-99-5
Sodium houttuyfonate is anti-pseudomonas agents, inhibits virulence-related motility of Pseudomonas.
- $53
Size
QTY
CASIN
Pirl1-related Compound 2
T3971425399-05-9
CASIN (Pirl1-related Compound 2) is a specific inhibitor of GTPase Cdc42 (IC50: 2 uM).
- $32
Size
QTY
Ketoconazole
Cited
Xolegel, R-41400, Extina, (±)-Ketoconazol
T067965277-42-1
Ketoconazole (R-41400), a CYP3A4 inhibitor, is an imidazole anti-fungal agent.
- $33
Size
QTY
Cited
RMC6236
T746982765081-21-6
RMC-6236 is a potent RAS(ON)MULTI inhibitor with broad-spectrum inhibitory activity against RAS-GTP and can be used in cancer research.
- $297
Size
QTY
Salirasib
S-Farnesylthiosalicylic acid, FTS, Farnesyl Thiosalicylic Acid
T6163162520-00-5
Salirasib (Farnesyl Thiosalicylic Acid)(Ki=2.6 μM), an effective competitive prenylated protein methyltransferase (PPMTase) inhibitor, inhibits Ras methylation with potential antineoplastic activity.
- $30
Size
QTY
(S)-(-)-Perillyl alcohol
T828218457-55-1
(S)-(−)-Perillyl alcohol (Perillyl alcohol), a monoterpene found in lavender, inhibits Ras farnesylation, upregulates the mannose-6-phosphate receptor, induces apoptosis, and exhibits anti-cancer activity.
- $31
Size
QTY
Vemurafenib Cited
RO5185426, RG7204, PLX4032
T2382918504-65-1
Vemurafenib (RG7204) is a B-RAF inhibitor that inhibits RAFV600E and c-RAF-1 (IC50=31/48 nM) selectively and potently. Vemurafenib exhibits antitumor activity and is used for the treatment of BRAF V600E mutation-positive melanoma.
- $50
Size
QTY
CitedCMPD1
T1498841179-33-3
CMPD1 is a non-ATP-competitive p38 MAPK-mediated MK2 phosphorylation inhibitor(apparent Ki (Kiapp): 330 nM).
- $31
Size
QTY
SKLB-163
SKLB163
T261931255099-06-9In house
SKLB-163 acts by downregulating RhoGDI, activating JNK-1 signaling pathway and caspase-3, and reducing phosphorylated Akt and p44/42 MAPK.
- $137
Size
QTY
Takinib Cited
EDHS-206
T42641111556-37-6
Takinib (EDHS-206) is a specific and effective TAK1 inhibitor(IC50= 9.5 nM).
- $66
Size
QTY
CitedRV01
T127811016897-10-1
RV01 is a novel quinoline-substituted analogue of resveratrol that inhibits DNA damage, reduces ethanol-induced acetaldehyde dehydrogenase (ALDH2) mRNA expression, and has hydroxyl radical scavenging activity. rV01 reduces iNOS expression and has anti-neuroinflammatory effects. rV01 reduces tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6) mRNA levels and secretion. RV01 reduced tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6) mRNA levels and secretion, inhibited lps-induced ROS production and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation, decreased toll-like receptor 4 (TLR4) protein expression, and inhibited lps-induced activation of mitogen-activated protein kinase (MAPK) and nuclear transcription factor-кB (NF-кB) signaling pathways.
- $56
Size
QTY
Select Batch
Purity:98.57%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | Pan-RAS-IN-1 is an inhibitor of pan-Ras. It disrupts the interaction of Ras proteins and their effectors. |
| In vitro | Pan-RAS-IN-1 is cytostatic, possibly due to pan-RAS inhibition at some concentrations. Pan-RAS-IN-1 is evaluated in primary T cell acute lymphoblastic leukemia (T-ALL) cells. Selective lethality is observed, with mutant NRAS cells retaining only 20%-40% viability after 5 μM treatment. Pan-RAS-IN-1 binds to KRasG12D-GppNHp with an affinity of less than 20 μM. Pan-RAS-IN-1 binds to Ras proteins and exhibits lethality in cells partially dependent on the expression of Ras proteins. The potency of pan-RAS-IN-1 correlates with the degree of dependency on the mutated isoform over a 5-fold concentration range [1]. |
| In vivo | Pan-RAS-IN-1-treated mice show decreased tumor pERK levels compared with vehicle-treated mice. Pan-RAS-IN-1 administration causes inhibition of tumor growth over 15 days of treatment. A modest increase in cleaved caspase-3 is also observed, showing that pan-RAS-IN-1 has the capacity to induce caspase activation in this model[1]. |
| Molecular Weight | 717.65 |
| Formula | C36H41Cl2F3N6O2 |
| Cas No. | 1835283-94-7 |
| Smiles | NC1(CCNCC1)C(=O)NCCCn1cc(-c2ccc(OC(F)(F)F)cc2)c2cc(CN3CCN(Cc4c(Cl)cccc4Cl)CC3)ccc12 |
| Relative Density. | 1.38 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (69.67 mM) | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Pan-RAS-IN-1 | purchase Pan-RAS-IN-1 | Pan-RAS-IN-1 cost | order Pan-RAS-IN-1 | Pan-RAS-IN-1 chemical structure | Pan-RAS-IN-1 in vivo | Pan-RAS-IN-1 in vitro | Pan-RAS-IN-1 formula | Pan-RAS-IN-1 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.